Tumour CD274 (PD-L1) expression and T cells in colorectal cancer

Gut

Volumn 66, Issue 8, 2017, Pages 1463-1473

  Masugi, Yohei ^a   Nishihara, Reiko ^a,b   Yang, Juhong ^a,c   Mima, Kosuke ^a   Da Silva, Annacarolina ^a   Shi, Yan ^a   Inamura, Kentaro ^d   Cao, Yin ^b,e   Song, Mingyang ^b,e   Nowak, Jonathan A ^f   Liao, Xiaoyun ^a   Nosho, Katsuhiko ^g   Chan, Andrew T ^e,f   Giannakis, Marios ^a,f,h   Bass, Adam J ^a,f,h   Hodi, F Stephen ^a   Freeman, Gordon J ^a,f   Rodig, Scott ^f   Fuchs, Charles S ^a,f   Qian, Zhi Rong ^a   Ogino, Shuji ^a,b,f   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d CANCER INSTITUTE   (Japan)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

CANCER EPIDEMIOLOGY; COLORECTAL CANCER; IMMUNE RESPONSE; MOLECULAR PATHOLOGY; T LYMPHOCYTES

Indexed keywords

B RAF KINASE; CD3 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR FOXP3; BACTERIAL DNA; CD274 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C;

AGED; ANTIGEN EXPRESSION; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DENSITY; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG INTERSPERSED REPEAT; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STROMA CELL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; CARCINOMA; CD8+ T LYMPHOCYTE; CHEMISTRY; COLON TUMOR; FUSOBACTERIUM NUCLEATUM; GENETICS; LYMPHOCYTE; LYMPHOCYTE COUNT; MIDDLE AGED; PATHOLOGY; RECTUM TUMOR; SURVIVAL RATE;

AGED; B7-H1 ANTIGEN; CARCINOMA; CD3 COMPLEX; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; DNA, BACTERIAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; FUSOBACTERIUM NUCLEATUM; HUMANS; LEUKOCYTE COMMON ANTIGENS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RECTAL NEOPLASMS; SURVIVAL RATE;

EID: 84966470555     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-311421     Document Type: Article

References (52)

1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 2015;27:450-61.
2. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
3. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.
4. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43-51.
5. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015;21:938-45.
6. Lal N, Beggs AD, Willcox BE, et al. An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology 2015;4:e976052.
7. Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology 2015;149:1204-25.e12.
8. Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14:16365-85.
9. Di Caro G, Marchesi F, Laghi L, et al. Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med 2013;17:1088-95.
10. Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol 2015;33:1787-96.
11. Ijspeert JE, Vermeulen L, Meijer GA, et al. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat Rev Gastroenterol Hepatol 2015;12:401-9.
12. Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers 2015. doi:10.1038/nrdp.2015.65
13. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology-Analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011;8:711-19.
14. Palmqvist R, Wikberg M, Ling A, et al. The association of immune cell infiltration and prognosis in colorectal cancer. Curr Colorectal Cancer Rep 2013;9:372-9.
15. Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010;222:350-66.
16. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
17. Mlecnik B, Bindea G, Angell HK, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 2014;6:228ra37.
18. Shang B, Liu Y, Jiang SJ, et al. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: A systematic review and meta-Analysis. Sci Rep 2015;5:15179.
19. Mei Z, Liu Y, Liu C, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-Analysis. Br J Cancer 2014;110:1595-605.
20. Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009;15:6412-20.
21. Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 2013;309:2563-71.
22. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
23. Nishihara R, Wu K, Lochhead P, et al. Long-Term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-105.
24. Yamauchi M, Lochhead P, Morikawa T, et al. Colorectal cancer: A tale of two sides or a continuum? Gut 2012;61:794-7.
25. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-42.
26. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
27. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008;3:e3698.
28. Imamura Y, Lochhead P, Yamauchi M, et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer 2014;13:135.
29. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012;18:2257-68.
30. Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol 2015;1:653-61.
31. Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut Published Online First: 26 Aug 2015. doi:10.1136/gutjnl-2015-310101
32. Zhao LW, Li C, Zhang RL, et al. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta Histochem 2014;116:1163-8.
33. Hua D, Sun J, Mao Y, et al. B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. World J Gastroenterol 2012;18:971-8.
34. Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf ) 2015;3:269-76.
35. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012;12:621-8.
36. Martinez-Useros J, Garcia-Foncillas J. Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med 2016;14:21.
37. Roy HK, Turzhitsky V, Wali R, et al. Spectral biomarkers for chemoprevention of colonic neoplasia: A placebo-controlled double-blinded trial with aspirin. Gut Published Online First: 26 Oct 2015. doi:10.1136/gutjnl-2015-309996
38. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the Immunoscore in the classification of malignant tumours. J Pathol 2014;232:199-209.
39. Mlecnik B, Bindea G, Angell HK, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 2016;44:698-711.
40. Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol 2014;14:154-65.
41. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: The paradox of colorectal cancer. Cancer Immunol Immunother 2011;60:909-18.
42. Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49:2233-42.
43. Liang M, Li J, Wang D, et al. T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast Chinas Heilongjiang province. Tumour Biol 2014;35:55-60.
44. Song M, Chen D, Lu B, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS ONE 2013;8:e65821.
45. Wu P, Wu D, Li L, et al. PD-L1 and survival in solid tumors: A meta-Analysis. PLoS ONE 2015;10:e0131403.
46. Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11:2947-53.
47. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13:2151-7.
48. Youngnak P, Kozono Y, Kozono H, et al. Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun 2003;307:672-7.
49. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-74.
50. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515: 563-7.
51. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411.
52. Ogino S, Nishihara R, VanderWeele TJ, et al. The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology 2016 (in press).